Bicycle Therapeutics (ADR) (BCYC)
Develops Bicycle Drug Conjugates and radioconjugates for precision oncology.
$4.30
At close+0.20 (+4.88%)
Something off on this page? Send us feedback.
Next report
Oct 29, 2026
estimated · in 56 days
EPS estimate
−$0.40
Revenue estimate
$12.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Oct '25Mar '26Apr '26Jul '26Oct '26
Reported−$0.80−$0.88−$1.14−$0.85−$0.29−$0.87−$0.72Pending
Estimate−$0.85−$0.86−$0.95−$1.09−$0.94−$0.58−$0.56−$0.40
Surprise+5.9%−2.3%−20.0%+22.0%+69.1%−51.0%−27.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Oct '25Mar '26Apr '26Jul '26Oct '26
Reported$3.7M$10.0M$2.9M$11.7M$48.0M$887.0K$629.0KPending
Estimate$7.3M$9.2M$8.4M$7.1M$7.0M$7.5M$4.2M$12.2M
Surprise−48.9%+8.0%−65.2%+65.8%+581.6%−88.2%−85.1%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$0.40 | — | — |
| Jul 2026 | −$0.56 | −$0.72 | −27.6% |
| Apr 2026 | −$0.58 | −$0.87 | −51.0% |
| Mar 2026 | −$0.94 | −$0.29 | +69.1% |
| Oct 2025 | −$1.09 | −$0.85 | +22.0% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | −$0.40 | — | — | $12.2M | — | — | — |
| Jul 30, 2026 | −$0.56 | −$0.72 | −27.6% | $4.2M | $629.0K | −85.1% | +3.9% |
| Apr 30, 2026 | −$0.58 | −$0.87 | −51.0% | $7.5M | $887.0K | −88.2% | +1.7% |
| Mar 17, 2026 | −$0.94 | −$0.29 | +69.1% | $7.0M | $48.0M | +581.6% | −7.3% |
| Oct 30, 2025 | −$1.09 | −$0.85 | +22.0% | $7.1M | $11.7M | +65.8% | −7.9% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||||||
| Aug 8, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 20, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 10, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 23, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||